<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398840</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ 171-101</org_study_id>
    <nct_id>NCT00398840</nct_id>
  </id_info>
  <brief_title>A Study of ARQ 171 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Dose Escalation Study of ARQ 171 in Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ArQule</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ArQule</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, dose escalation study of ARQ 171 administered via intravenous infusion
      (IVI) into a peripheral vein weekly.

      Patients with advanced solid tumors, who are refractory to available therapy or for whom no
      standard systemic therapy exists, will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">November 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety, tolerability and maximum tolerated dose (MTD) of ARQ 171</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetic profile of ARQ 171</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary anti-tumor activity of ARQ 171</measure>
  </secondary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ 171</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent must be obtained and documented prior to
             study-specific screening procedures.

          -  A histologically or cytologically confirmed advanced solid tumor

          -  ≥ 18 years of age

          -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors

          -  Karnofsky performance status ≥ 70%

          -  Male or female patients of child-producing potential must agree to use contraception
             or avoidance of pregnancy measures during the study and for 30 days after
             participation.

          -  Females of childbearing potential must have a negative serum pregnancy test.

          -  Laboratory results must meet study criteria.

        Exclusion Criteria:

          -  Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents
             within four weeks of first infusion

          -  Surgery within 4 weeks prior to first infusion

          -  Known untreated brain metastases

          -  Pregnant or breastfeeding

          -  Uncontrolled intercurrent illness, or uncontrolled infection or psychiatric
             illness/social situations that would limit compliance with study requirements

          -  Other cancer within the last five years, with the exception of adequately treated
             cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell
             carcinoma of the skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Premiere Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber/Harvard Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2006</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <name_title>Arqule</name_title>
    <organization>Arqule, Inc.</organization>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>advanced solid tumors</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

